Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.
You may also be interested in...
Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Chief exec sits down with “The Pink Sheet” DAILY at BIO Investor Forum to discuss lead candidates in oncology and heart failure, and partnering with big pharma.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.